Bladder cancer pharmacogenomics: recent insights and future perspectives.

about

Pharmacogenomics in bladder cancer.Diagnostic Microdosing Approach to Study Gemcitabine Resistance.Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer.

P2860

Q37523551-D41E1E8F-FAAE-43C5-BCEF-92AD6E4016A8 Q38744400-6BD30A31-9D87-4D62-8A55-9FCD5C01DDEC Q39790653-C79CD3ED-EF85-4740-A86A-7F45F724178B

P2860

Bladder cancer pharmacogenomics: recent insights and future perspectives.

Item

http://www.wikidata.org/entity/Q51540087

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Bladder cancer pharmacogenomics: recent insights and future perspectives.

@en

Bladder cancer pharmacogenomics: recent insights and future perspectives.

@nl

type

Item

label

Bladder cancer pharmacogenomics: recent insights and future perspectives.

@en

Bladder cancer pharmacogenomics: recent insights and future perspectives.

@nl

prefLabel

Bladder cancer pharmacogenomics: recent insights and future perspectives.

@en

Bladder cancer pharmacogenomics: recent insights and future perspectives.

@nl

P1476

Bladder cancer pharmacogenomics: recent insights and future perspectives.

@en

P2093

Peter H O'Donnell

http://www.w3.org/2001/XMLSchema#string

P2860

Germline pharmacogenomics in oncology: decoding the patient for targeting therapy

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy

Prediction of drug combination chemosensitivity in human bladder cancer.

A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration.

Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling.

Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.

Study of the prediction system for clinical response to M-VAC neoadjuvant chemotherapy for bladder cancer.

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

P304

1553-1556

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.2217/PGS.12.145

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23148629

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics

Bladder cancer pharmacogenomics: recent insights and future perspectives.

about

P2860

P2860

Bladder cancer pharmacogenomics: recent insights and future perspectives.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921